Introduction {#sec1-1}
============

Diabetes mellitus is a pandemic disease that has struck each and every corner of the world. According to the Indian Council of Medical Research-Indian Diabetes study (ICMR), a national diabetes study, India currently has 62.4 million people with diabetes.\[[@ref1]\] This is set to increase to over 100 million by 2030.\[[@ref2]\] The prevalence of diabetes among adults has reached approximately 20% in urban and approximately 10% in rural populations in India.\[[@ref3]\]

Various classes of anti-diabetic drugs including insulin and oral hypoglycemic agents (OHA) are currently used in the treatment of diabetes, which acts by different mechanisms to reduce the blood-glucose levels to maintain optimal glycemic control.\[[@ref4][@ref5]\]

The United Kingdom Prospective Diabetes Study showed intensive blood-glucose control by either sulfonylureas or insulin substantially decreased the risk of microvascular complications.\[[@ref6][@ref7]\]

The currently used anti-diabetic drugs are very effective, however because of lack of patient compliance, clinical inertia, insulin resistance, lack of exercise and lack of dietary control leads to unsatisfactory control of hyperglycemia.\[[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] In India, limited studies have focused on diabetes care and provide an insight into the current profile of patients and their management. More than 50% of people with diabetes have poor glycemic control, uncontrolled hypertension and dyslipidemia, and a large percentage have diabetic vascular complications.\[[@ref16][@ref17]\]

Therefore, this study was carried out to find the current prescribing pattern of anti-diabetic drugs and efficacy of these drugs in maintaining adequate glycemic control in diabetic patients attending a tertiary care teaching hospital in Navi Mumbai.

Materials and Methods {#sec1-2}
=====================

This was a cross-sectional, prospective, observational study carried out in Diabetology and Medicine Department of a Tertiary Care Hospital in Navi Mumbai and was conducted for the ICMR Short Term Research Studentship (2010) program. Permission from ethics committee was obtained prior to the conduct of the study. The sample size for this study was 100 patients (95% confidence interval, ±10%) in accordance with World Health Organization (WHO) manual to assess drug use in individual facilities.\[[@ref18]\] It was a pilot study with duration of 2 months (May 10, 2010 to July 10, 2010) in which 100 patients of diabetes of 18 years and above receiving anti-diabetic therapy for more than 1 year was randomly selected for participation after fulfilling inclusion/exclusion criteria. After obtaining informed consent, sociodemographic data along with details of anti-diabetic drug therapy, duration of treatment and life style modifications (dieting/exercise/both) was recorded. In addition, fasting and postprandial blood-glucose was measured by Accu-Chek Active glucometer. We excluded newly diagnosed diabetic patients, diabetic patient on anti-diabetic therapy for \<1 year, diabetic coma patients, repeat attendance, patients not willing for informed consent and blood-glucose investigation.

The following parameters were analyzed:

Average number of anti-diabetic drugs per prescription, percentage of different class of anti-diabetic drug prescribed, commonest class and type of anti-diabetic drugs prescribed, percentage of anti-diabetic drugs prescribed from essential drug list (WHO and Indian National Essential Drug List).\[[@ref19][@ref20]\] Patients were categorized with optimal controlled glycemic level based upon the blood-glucose level (fasting \<100 mg/dL and/or postprandial \<180 mg/dL) measured by Accu-Chek Active glucometer.

The study data were analyzed on the Statistical Package for the Social Sciences version 17 (Chicago: SPSS Inc), with *P* \< 0.05 was considered to be statistically significant. Chi-square test was used for categorical data to test for the association. Data were expressed in terms of the actual number, mean, and percentages.

Results {#sec1-3}
=======

One hundred (*n* = 100) patients of Type 2 diabetes were analyzed and 140 anti-diabetic drug products were prescribed. Male were 54% (*n* = 54), female were 46% (*n* = 46) and the mean age of the sample was 58.12 (±10.5) years.

Prescribing pattern {#sec2-1}
-------------------

During the study, the number of anti-diabetic drug products per prescription varied from one to four and the average number of anti-diabetic drugs per prescription was 1.4.

Out of total 140 prescribed anti-diabetic drug products, 79 (56.4%) were OHA and 61 (43.6%) were insulin \[[Figure 1](#F1){ref-type="fig"}\]. Thus OHA\'s were the most common class of anti-diabetic drugs prescribed in this study. Sulfonylureas (34.14%) were the most commonly prescribed class followed by biguanides (31.65%) among the different classes of OHA \[[Figure 2](#F2){ref-type="fig"}\] and their fixed dose combination (FDC) accounted for 20.25%. Metformin (biguanide) was the most common individual OHA to be prescribed 31.65%, followed by glimepiride (sulfonylurea) 20.25%, followed by FDC of glimepiride plus metformin 11.40% \[[Table 1](#T1){ref-type="table"}\]. Other classes of OHA prescribed were thiazolidinediones 6.33%, alpha glucosidase inhibitor 3.8%, and dipeptidyl peptidase 4 inhibitors (DPP 4 inhibitors) 2.5%, respectively. Insulin preparations accounted for 43.6% of the total anti-diabetic drugs and the most common preparation was short acting insulin preparation \[[Figure 3](#F3){ref-type="fig"}\].
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Prescribing frequency of different OHAs
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![Prescribing frequency of different preparations of insulin (*n* = 61)](JBCP-5-79-g004){#F3}

Brand versus generic and selection of essential drugs {#sec2-2}
-----------------------------------------------------

All the drugs were prescribed by brand names (100%). Percentage of drugs prescribed from WHO essential drug list was 74.2% (104) and National Essential Drug List of India was 67.1% (94).

Optimal glycemic control {#sec2-3}
------------------------

Of the 100 Type 2 diabetic patients who were receiving anti-diabetic drugs, 41 (41%) had controlled optimal glycemic levels, while 59 (59%) had inadequately controlled glycemic levels \[[Table 2](#T2){ref-type="table"}\]. Association between optimal glycemic levels was statistically significant in diabetic patients on anti-diabetic therapy with lifestyle modification (*P* = 0.0011); however, this association with type of therapy and duration of treatment was not significant statistically (*P* \> 0.05).

###### 

Characteristics of diabetic patients based on glycemic control
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Discussion {#sec1-4}
==========

In this study, an attempt has been made to describe the current prescribing pattern and trend of anti-diabetic drug therapy along with the efficacy of these drugs in maintaining an optimal glycemic level in diabetic patients in a tertiary care hospital in Navi Mumbai.

In this study, out of 100 patients who were treated with anti-diabetic drugs all of them were Type 2 diabetic patients (noninsulin dependent diabetes mellitus) that reflect the increasing prevalence of Type 2 diabetes mellitus in our region.

The average number of anti-diabetic drugs per prescription in this study was 1.4. Previous hospital based studies in India and Abroad has reported 2-5 drugs per prescription.\[[@ref21][@ref22][@ref23][@ref24][@ref25][@ref26]\] Our study showed restraint on polypharmacy.

In this study, OHAs were commonly prescribed drugs accounting for 56.40% of the total prescribed anti-diabetic products. Sulfonylureas (34.14%) were the most commonly prescribed class, which was similar to previous studies,\[[@ref22][@ref24][@ref27]\] followed by biguanides (31.65%) and their FDC accounted for 20.25%. This reflects that sulfonylureas and biguanides are still the choice of most physicians in the treatment of Type 2 diabetes.

In spite of sulfonylurea being the commonest class, we observed that metformin (biguanide) was the most common individual OHA to be prescribed 31.65% which is similar to several studies\[[@ref21][@ref23][@ref27][@ref28][@ref29]\] followed by glimepiride (sulfonylurea) 20.25%. This may be due to the fact that metformin was the only drug of its class to be prescribed, whereas many second generation sulfonylureas are available and were prescribed making their individual frequency low but as a group/class their prescribing was higher than biguanide class. The study documented low prescribing frequency of newer OHA (thiazolidinedione and DPP 4 inhibitors). They were used in combination with other OHAs in order to achieve better glycemic control which was similar to previous studies.\[[@ref22][@ref28]\]

Insulin preparations accounted for 43.6% of the total anti-diabetic drugs and the most common preparation was short acting insulin preparation. We found a higher percentage of insulin prescribing and insulin based therapy in our study compared with previous Indian studies.\[[@ref23][@ref24]\] Insulin preparations can provide intensive, near-physiologic delivery of insulin and can help patients achieve better glycemic control.\[[@ref30]\] This reflects a change in prescribing trend and shift toward insulin based therapy from the dominated class of OHA in Type 2 diabetes treatment.

In this study, all drugs were prescribed by brand name suggesting popularity of the brands among the physician and influence of pharmaceutical companies on the physician. It is advisable to prescribe by generic name for cost effective utilization. However, in this study the percentage of drugs prescribed from national essential drug list was 67.1% which showed the awareness and selection of drugs from essential drug list for rational use of drugs.

About 41% patients on anti-diabetic drugs had controlled optimal glycemic levels, while 59% had inadequate/uncontrolled glycemic levels. Several studies\[[@ref15][@ref31][@ref32][@ref33][@ref34]\] have documented from 50% to 86%, which were higher than our studies. Although these variations across studies may be true, they may also be due to differences in populations surveyed, methods of data collection, measurements of blood-glucose/hemoglobin A1c (HbA1c), and definitions of blood-glucose/HbA1c cut-point for adequate glycemic control.

The most prevalent anti-diabetic therapy was monotherapy either with OHA or insulin, while combination therapy with OHA\'s and insulin was to a lesser extent. Study by Willey *et al*.,\[[@ref32]\] has documented good glycemic control on monotherapy. However in our study, association of glycemic control with monotherapy and combination therapy was not statistically significant (*P* \> 0.05). However, we found a statistically significant association between glycemic control and anti-diabetic drug therapy with lifestyle modification. Thus, lifestyle modification along with anti-diabetic drug treatment has the potential to improve glycemic control in patients with Type 2 diabetes despite optimized anti-diabetic drug treatment.\[[@ref6][@ref7][@ref35]\]

The study strongly highlights the domination of OHA but documents shifting trend towards insulin in the treatment of Type 2 diabetes and the need for periodic blood-glucose monitoring in patients receiving anti-diabetic drug treatment to identify inadequately controlled glycemic levels, so that drug therapy can be intensified and multiple drug interventions can be planned in order to obtain an optimal glycemic level. It also highlights the need for lifestyle modification measures along with anti-diabetic drug treatment for achieving better glycemic control in Type 2 diabetes.

Limitations of the Study {#sec1-5}
========================

It was a pilot study of 2 months duration conducted in 100 diabetic patients. Measurement of HbA1c level, which is considered as the gold standard and gives better judgment about 3 months glycemic control, was not done due to its high cost. Measurement of blood-glucose was done with Accu-Chek Active glucometer instead of laboratory glucose oxidase-peroxidase method. Accu-Chek Active glucometer was used due to its ease of self-monitoring of blood-glucose and it correlated well with the laboratory blood-glucose values.\[[@ref36]\]

Conclusion {#sec1-6}
==========

Oral hypoglycemic agents still dominate the prescribing pattern, but there was a shifting trend toward the use of insulin preparations in the management of Type 2 diabetes mellitus. In achieving optimal glycemic control, the efficacy of the anti-diabetic drugs was only 41%; therefore intensification of current drug treatment as well as planning multiple drug interventions with lifestyle modification is necessary to prevent diabetic complications.
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